...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Breast cancer research and treatment. >Comparative Analysis Between the HER2 Status in Primary Breast Cancer Tissue and the Detection of Isolated Tumor Cells in the Bone Marrow.
【24h】

Comparative Analysis Between the HER2 Status in Primary Breast Cancer Tissue and the Detection of Isolated Tumor Cells in the Bone Marrow.

机译：原发性乳腺癌组织中HER2状态与骨髓中分离的肿瘤细胞检测之间的比较分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The presence of isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients is an independent prognostic parameter, indicating hematogenous tumor cell dissemination. While the HER2 status of breast cancer tissue has predictive value for the efficacy of different therapies, its prognostic relevance is controversial. To investigate the relationship between HER2 and ITC-BM, we retrospectively analyzed tumor tissues of 327 patients who underwent bone marrow aspiration at primary diagnosis or during the disease-free interval. Screening for ITC-BM was performed immunocytochemically, using the anti-cytokeratin antibody A45 B/B3. HER2 was determined by immunohistochemistry (IHC) with the antibody CB 11 ( n = 277) and by fluorescence in situ hybridization (FISH, PathVision, Vysis, n = 206).ITC-BM were found in 83 of 327 patients (25.4%), with a median of 2.0 per 2 x 10(6 )mononuclear cells. HER2 positivity (2+ /3+ ) was demonstrated in 18.8% of the tumors, amplification by FISH in 56 of 206 cases(27.2%). Established pathological parameters,tiviathological parameters, such as tumor size ( p = 0.15), lymph node status ( p = 0.93) and HER2 did not predict the presence of ITC-BM. After a median follow-up of 49months (1-255), the presence of ITC-BM was a significant prognostic factor for distant disease free and overall survival, as well in univariate (log-rank-test, p = 0.024) as in multivariate analysis (cox-regression, p = 0.033 ). This also was confirmed in subgroups of patients by aease free survival ( p = 0.013) and local recurrence ( p = 0.003).The detection of ITC-BM is superior in predicting overall survival, compared to the HER2 status of the primary tumor. The direct identification of HER2 on ITC-BM is the aim of ongoing research, potentially synergizing the prognostic relevance of ITC-BM and the predictive value of the HER2 status.
机译：乳腺癌患者的骨髓（ITC-BM）中是否存在分离的肿瘤细胞是一个独立的预后参数，表明血肿性肿瘤细胞的扩散。尽管乳腺癌组织的HER2状态对于不同疗法的疗效具有预测价值，但其预后相关性仍存在争议。为了研究HER2与ITC-BM之间的关系，我们回顾性分析了327例在初次诊断或无病间隔期间接受骨髓穿刺术的患者的肿瘤组织。使用抗细胞角蛋白抗体A45 B / B3对细胞进行ITC-BM筛选。 HER2是通过免疫组织化学（IHC）与抗体CB 11（n = 277）以及荧光原位杂交（FISH，PathVision，Vysis，n = 206）确定的，在327例患者中有83例（25.4％）发现了ITC-BM ，每2 x 10（6）个单核细胞的中位数为2.0。 HER2阳性（2+ / 3 +）在18.8％的肿瘤中得到证实，在206例病例中有56例（27.2％）通过FISH扩增。建立的病理学参数，病理学参数，例如肿瘤大小（p = 0.15），淋巴结状态（p = 0.93）和HER2不能预测ITC-BM的存在。在中位随访49个月（1-255）之后，ITC-BM的存在是远期无疾病和总体生存的重要预后因素，单变量（log-rank-test，p = 0.024）与多元分析（cox回归，p = 0.033）。通过无酶生存率（p = 0.013）和局部复发（p = 0.003）在患者亚组中也证实了这一点。与原发肿瘤的HER2状态相比，ITC-BM的检测在预测总体生存率方面具有优势。在ITC-BM上直接鉴定HER2是正在进行的研究的目标，可能使ITC-BM的预后相关性与HER2状况的预测价值协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号